Several other analysts also recently commented on VRX. Jefferies Group LLC set a $18.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a buy rating in a report on Saturday, May 6th. Piper Jaffray Companies reiterated an underweight rating and issued a $10.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Friday. J P Morgan Chase & Co reiterated a neutral rating and issued a $10.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Thursday, July 6th. Guggenheim initiated coverage on shares of Valeant Pharmaceuticals International in a research note on Saturday, June 17th. They issued a buy rating and a $18.00 price objective for the company. Finally, TD Securities lifted their price objective on shares of Valeant Pharmaceuticals International from $15.00 to $20.00 and gave the stock a hold rating in a research note on Wednesday, July 12th. Four analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Valeant Pharmaceuticals International presently has an average rating of Hold and an average target price of $16.81.
Valeant Pharmaceuticals International (NYSE VRX) traded up 0.75% during trading on Friday, hitting $17.37. The stock had a trading volume of 14,901,404 shares. Valeant Pharmaceuticals International has a 52-week low of $8.31 and a 52-week high of $32.74. The stock’s market capitalization is $6.04 billion. The stock’s 50-day moving average is $13.59 and its 200-day moving average is $12.98.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 EPS for the quarter, topping the consensus estimate of $0.87 by $1.93. The business had revenue of $2.11 billion during the quarter, compared to the consensus estimate of $2.17 billion. Valeant Pharmaceuticals International had a negative net margin of 14.96% and a positive return on equity of 58.02%. Valeant Pharmaceuticals International’s revenue was down 11.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.08) EPS. On average, analysts predict that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Given Sell Rating at Wells Fargo & Company” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/07/17/valeant-pharmaceuticals-international-inc-nysevrx-given-sell-rating-at-wells-fargo-company.html.
In related news, Director Schutter Richard U. De purchased 20,000 shares of the business’s stock in a transaction that occurred on Thursday, May 11th. The shares were acquired at an average price of $13.90 per share, for a total transaction of $278,000.00. Following the completion of the acquisition, the director now directly owns 70,572 shares in the company, valued at approximately $980,950.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 5.87% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. Gruss & Co. Inc. bought a new stake in Valeant Pharmaceuticals International during the first quarter valued at $104,000. Financial Architects Inc boosted its stake in Valeant Pharmaceuticals International by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock valued at $105,000 after buying an additional 1,500 shares during the period. Harbor Advisors LLC bought a new stake in Valeant Pharmaceuticals International during the first quarter valued at $110,000. WMS Partners LLC bought a new stake in Valeant Pharmaceuticals International during the first quarter valued at $116,000. Finally, Brave Asset Management Inc. bought a new stake in Valeant Pharmaceuticals International during the first quarter valued at $119,000. Institutional investors and hedge funds own 50.45% of the company’s stock.
About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
What are top analysts saying about Valeant Pharmaceuticals International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Valeant Pharmaceuticals International Inc. and related companies.